These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. Albert NM Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340 [TBL] [Abstract][Full Text] [Related]
7. A new era of antithrombotic therapy in patients with atrial fibrillation. Golwala H; Dib C; Tafur A; Abu-Fadel MS Am J Med Sci; 2012 Aug; 344(2):128-35. PubMed ID: 22245946 [TBL] [Abstract][Full Text] [Related]
8. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation. Deedwania PC; Huang GW Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079 [TBL] [Abstract][Full Text] [Related]
10. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
11. [New treatments for stroke and thromboembolism prevention in atrial fibrillation]. Shiyovich A; Khalameizer V; Katz A Harefuah; 2014 Jan; 153(1):32-8, 64. PubMed ID: 24605405 [TBL] [Abstract][Full Text] [Related]
12. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants? Escobar C; Barrios V; Jimenez D Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760 [TBL] [Abstract][Full Text] [Related]
16. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY; Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063 [TBL] [Abstract][Full Text] [Related]
17. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Becattini C; Vedovati MC; Agnelli G Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937 [TBL] [Abstract][Full Text] [Related]
18. [Anticoagulation in atrial fibrillation. Strategies in special situations]. Volkmann H; Walter M; Walter C; Vetter S Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179 [TBL] [Abstract][Full Text] [Related]
19. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Huisman MV; Lip GY; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Teutsch C; Zint K; Ackermann D; Clemens A; Bartels DB Am Heart J; 2014 Mar; 167(3):329-34. PubMed ID: 24576516 [TBL] [Abstract][Full Text] [Related]
20. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]